Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Regulus Therapeutics Inc. buy Wells Fargo & Company

Start price
€1.49
27.03.25 / 50%
Target price
€5.57
27.03.26
Performance (%)
373.15%
End price
-
28.03.26
Summary
This prediction is currently being closed. With a performance of 373.15% the BUY prediction by Wells_Fargo___Compan is a big success. Wells_Fargo___Compan has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Regulus Therapeutics Inc. - - -
iShares Core DAX® 0,75 % -8,50 % 2,57 %
iShares Nasdaq 100 -1,41 % -2,77 % 15,68 %
iShares Nikkei 225® 0,42 % -9,29 % 29,65 %
iShares S&P 500 -0,59 % -2,87 % 9,96 %

Comments by Wells_Fargo___Compan for this prediction

In the thread Regulus Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 373.15%
Target price 5.573
Change
Ends at 27.03.26

Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $3.00.
Ratings data for RGLS provided by MarketBeat

In the thread Trading Regulus Therapeutics Inc.
Prediction Buy
Perf. (%) 373.15%
Target price 5.573
Change
Ends at 27.03.26

Die von Wells_Fargo___Compan gewählte maximale Laufzeit wurde überschritten